Literature DB >> 20389259

The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.

Ruoh-Fang Yen1, Chih-Yu Chen, Mei-Fang Cheng, Yen-Wen Wu, Yu-Chien Shiau, Karl Wu, Ruey-Long Hong, Chong-Jen Yu, Kao-Lun Wang, Rong-Sen Yang.   

Abstract

BACKGROUND: The aim of this prospective study is to evaluate the diagnostic and prognostic usefulness of F-18 sodium fluoride (NaF) positron emission tomography-computed tomography (PET-CT) relative to Tc-99m methylene diphosphonate (MDP) planar bone scintigraphy with no CT (BS) for hepatocellular carcinoma (HCC) patients with suspicious bone metastasis.
METHODS: Both Tc-99m MDP BS and F-18 NaF PET-CT were performed for 34 consecutive Taiwanese HCC patients (five female and 29 male; mean age, 61.0+/-12.0 years) within a time span of 1 month (mean: 11.3+/-10.4 days). The accuracies of BS and PET-CT were determined by comparing their results with the finalized clinical data in a lesion-by-lesion manner.
RESULTS: According to the pathological and/or follow-up results, the accuracy for detecting metastatic bone lesions by Tc-99m MDP BS is 75.4% and that by F-18 NaF PET-CT is 95.7%, respectively. F-18 NaF PET-CT is significantly more accurate than Tc-99m MDP BS (P=0.0001). Furthermore, there is a significant correlation between the presence of F-18 NaF PET-CT-positive bone lesions and the survival time of HCC patients. On the other hand, the diagnostic results from BS are not correlated with the survival time of these HCC patients.
CONCLUSION: F-18 NaF using PET-CT system has significantly better sensitivity and specificity than conventional Tc-99m MDP BS in detecting metastatic HCC bone lesions that are predominantly osteolytic. The diagnostic result of PET-CT also serves as a more effective prognostic indictor for HCC patients. 2010 Wolters Kluwer Health / Lippincott Williams & Wilkins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20389259     DOI: 10.1097/MNM.0b013e3283399120

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  16 in total

Review 1.  Review of functional/anatomical imaging in oncology.

Authors:  Stephanie N Histed; Maria L Lindenberg; Esther Mena; Baris Turkbey; Peter L Choyke; Karen A Kurdziel
Journal:  Nucl Med Commun       Date:  2012-04       Impact factor: 1.690

2.  Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.

Authors:  Gang Cheng; Thomas C Kwee; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-22       Impact factor: 9.236

3.  (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging.

Authors:  M Beheshti; F M Mottaghy; F Paycha; F F F Behrendt; T Van den Wyngaert; I Fogelman; K Strobel; M Celli; S Fanti; F Giammarile; B Krause; W Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-23       Impact factor: 9.236

4.  CT temporal subtraction improves early detection of bone metastases compared to SPECT.

Authors:  Koji Onoue; Mizuho Nishio; Masahiro Yakami; Gakuto Aoyama; Keita Nakagomi; Yoshio Iizuka; Takeshi Kubo; Yutaka Emoto; Thai Akasaka; Kiyohide Satoh; Hiroyuki Yamamoto; Hiroyoshi Isoda; Kaori Togashi
Journal:  Eur Radiol       Date:  2019-03-19       Impact factor: 5.315

5.  AEG-1 promoter-mediated imaging of prostate cancer.

Authors:  Akrita Bhatnagar; Yuchuan Wang; Ronnie C Mease; Matthew Gabrielson; Polina Sysa; Il Minn; Gilbert Green; Brian Simmons; Kathleen Gabrielson; Siddik Sarkar; Paul B Fisher; Martin G Pomper
Journal:  Cancer Res       Date:  2014-08-21       Impact factor: 12.701

6.  Sodium 18F-fluoride PET/CT of bone, joint, and other disorders.

Authors:  Hossein Jadvar; Bhushan Desai; Peter S Conti
Journal:  Semin Nucl Med       Date:  2015-01       Impact factor: 4.446

7.  Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study.

Authors:  Naotoshi Ota; Katsuhiko Kato; Shingo Iwano; Shinji Ito; Shinji Abe; Naotoshi Fujita; Keiichi Yamashiro; Seichi Yamamoto; Shinji Naganawa
Journal:  Br J Radiol       Date:  2014-02       Impact factor: 3.039

8.  Evaluation of bone-seeking novel radiotracer 68Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breast.

Authors:  Averilicia Passah; Madhavi Tripathi; Sanjana Ballal; Madhav Prasad Yadav; Rajeev Kumar; Frank Roesch; Marian Meckel; Partha Sarathi Chakraborty; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-25       Impact factor: 9.236

9.  The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.

Authors:  Nishikant Avinash Damle; Chandrasekhar Bal; G P Bandopadhyaya; Lalit Kumar; Praveen Kumar; Arun Malhotra; Sneh Lata
Journal:  Jpn J Radiol       Date:  2013-02-02       Impact factor: 2.374

10.  ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy.

Authors:  Daniel C Bortot; Bárbara J Amorim; Glaucia C Oki; Sérgio B Gapski; Allan O Santos; Mariana C L Lima; Elba C S C Etchebehere; Marycel F Barboza; Jair Mengatti; Celso Dario Ramos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.